Expert Consensus Document: Cholangiocarcinoma: Current Knowledge and Future Perspectives Consensus Statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2016 Apr 21

PMID 27095655

Citations 646

Authors

Jesus M Banales

Vincenzo Cardinale

Guido Carpino

Marco Marzioni

Jesper B Andersen

Pietro Invernizzi

Guro E Lind

Trine Folseraas

Stuart J Forbes

Laura Fouassier

Andreas Geier

Diego F Calvisi

Joachim C Mertens

Michael Trauner

Antonio Benedetti

Luca Maroni

Javier Vaquero

Rocio I R Macias

Chiara Raggi

Maria J Perugorria

Eugenio Gaudio

Kirsten M Boberg

Jose J G Marin

Domenico Alvaro

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the "European Network for the Study of Cholangiocarcinoma" (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational and clinical level. In this Consensus Statement, we aim to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer. Moreover, future directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.

Citing Articles

Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization.

Jaidee R, Jusakul A, Pocasap P, Kukongviriyapan V, Senggunprai L, Prawan A Sci Rep. 2025; 15(1):8621.

PMID: 40074934 PMC: 11904213. DOI: 10.1038/s41598-025-93192-1.

Choledocholithiasis as a risk factor for cholangiocarcinoma: a nationwide retrospective cohort study.

Kim J, Lee Y, Lee J, Hwang J BMC Gastroenterol. 2025; 25(1):138.

PMID: 40045214 PMC: 11883955. DOI: 10.1186/s12876-025-03746-w.

Characteristics of gut microbiota and metabolites in extrahepatic cholangiocarcinoma and their prognostic value for resectable lesions.

Ye C, Zhang B, Lin Y, Han F, Shi H, Dong C Front Cell Infect Microbiol. 2025; 15:1523863.

PMID: 40028184 PMC: 11868125. DOI: 10.3389/fcimb.2025.1523863.

Clinical significance of para-aortic lymph node metastasis for prognosis in patients with pancreaticobiliary cancer who underwent radical surgical resections.

Nanashima A, Arai J, Hiyoshi M, Imamura N, Hamada T, Tsuchimochi Y Turk J Surg. 2025; 41(1):5-18.

PMID: 40012245 PMC: 11878181. DOI: 10.47717/turkjsurg.2025.6587.

The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study.

Cai Y, Wen W, Xia Y, Wan R Curr Oncol. 2025; 32(2).

PMID: 39996887 PMC: 11854701. DOI: 10.3390/curroncol32020087.

References

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

Gradilone S, Radtke B, Bogert P, Huang B, Gajdos G, LaRusso N . HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res. 2013; 73(7):2259-70. PMC: 3768151. DOI: 10.1158/0008-5472.CAN-12-2938. View

Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim H . CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010; 120(9):3326-39. PMC: 2929722. DOI: 10.1172/JCI42550. View

Lindor K, Kowdley K, Harrison M . ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015; 110(5):646-59. DOI: 10.1038/ajg.2015.112. View

Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, Bhudhisawasdi V . Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005; 11(18):2748-53. PMC: 4305909. DOI: 10.3748/wjg.v11.i18.2748. View

Han K, Ko H, Kim K, Won H, Shin Y, Kim P . Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol. 2015; 26(7):943-8. DOI: 10.1016/j.jvir.2015.02.024. View

Rullier A, Le Bail B, Fawaz R, Blanc J, Saric J, Bioulac-Sage P . Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol. 2000; 24(6):870-6. DOI: 10.1097/00000478-200006000-00014. View

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B . Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013; 144(4):829-40. PMC: 3624083. DOI: 10.1053/j.gastro.2013.01.001. View

10.

Zaydfudim V, Rosen C, Nagorney D . Hilar cholangiocarcinoma. Surg Oncol Clin N Am. 2014; 23(2):247-63. DOI: 10.1016/j.soc.2013.10.005. View

11.

Carpino G, Cardinale V, Onori P, Franchitto A, Berloco P, Rossi M . Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat. 2011; 220(2):186-99. PMC: 3275774. DOI: 10.1111/j.1469-7580.2011.01462.x. View

12.

Magee J, Piskounova E, Morrison S . Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012; 21(3):283-96. PMC: 4504432. DOI: 10.1016/j.ccr.2012.03.003. View

13.

Maroni L, Alpini G, Marzioni M . Cholangiocarcinoma development: the resurgence of bile acids. Hepatology. 2014; 60(3):795-7. DOI: 10.1002/hep.27223. View

14.

Ohira S, Sasaki M, Harada K, Sato Y, Zen Y, Isse K . Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol. 2006; 168(4):1155-68. PMC: 1606561. DOI: 10.2353/ajpath.2006.050204. View

15.

Boberg K, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U . Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002; 37(10):1205-11. DOI: 10.1080/003655202760373434. View

16.

Hwang I, Jang J, Do J, Kang J, Lee G, Oh S . Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients. Cancer Chemother Pharmacol. 2011; 68(4):935-44. DOI: 10.1007/s00280-011-1558-3. View

17.

Saborowski A, Saborowski M, Davare M, Druker B, Klimstra D, Lowe S . Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A. 2013; 110(48):19513-8. PMC: 3845141. DOI: 10.1073/pnas.1311707110. View

18.

Yamasaki S . Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003; 10(4):288-91. DOI: 10.1007/s00534-002-0732-8. View

19.

Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei X . Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010; 101(8):1913-9. PMC: 11158749. DOI: 10.1111/j.1349-7006.2010.01614.x. View

20.

Yamada D, Ilyas S, Razumilava N, Bronk S, Davila J, Champion M . IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology. 2015; 61(5):1627-42. PMC: 4406813. DOI: 10.1002/hep.27687. View